SYNTHESIS OF MACROCYCLES STEROIDS CYCLOPENTANOIDS ETC
大环类固醇环戊烷等的合成
基本信息
- 批准号:2385645
- 负责人:
- 金额:$ 44.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1987
- 资助国家:美国
- 起止时间:1987-06-01 至 2002-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: Exploring biological phenomena at a molecular level provides
the basis of understanding from which new therapeutic agents derive. The
ability to construct a defined molecular architecture requires highly
selective reactions and reagents to permit the development of effective
synthetic strategies. Cyclic compounds have biological activities across a
broad spectrum. Furthermore, constraining conformations of mobile molecules
by forming rings also frequently enhances biological potency. Thus, a
concerted effort to apply new chemical principles being developed in the
PI's laboratories to the formation of rings becomes an important objective.
In the first phase, a new concept to create macrocycles (rings larger than
seven members) may provide a unique opportunity to approach a variety of
significant targets. Some examples include the antiinflammatory nine
membered macrolides ascidiatrienolides, the antitumor eight membered
carbocycles, the shikoccins, and the azocines, FR-99048 and FR-66979, the
ten membered macrolactam neuropeptidase inhibitor CGS-25155,the fourteen
membered antiviral and antifungal fluviricinines, and the nineteen membered
serine protease inhibitors, the cyclotheonamides. In the second phase, a
new reactivity mode for shuffling protons in totally unconventional methods
offers novel approaches to cyclizations. Vitamin D analogues and
derivatives represent a most important direction for creation of clinically
important therapeutic agents. A new concept for their synthesis based upon
novel strategies for asymmetric induction will be pursued. A variation on
this methodology may extend the reaction to a facile asymmetric synthesis of
either cis or trans fused drimanes and related classes of terpenoids from a
common intermediate, a class of compounds that have remarkably broad
biological activities including antibacterial, antifungal, antimalarial,
antiinflammatory, cytotoxic, and insecticidal. A new class of reactions
provides a novel atom economical approach for formation of heterocycles.
This invention stimulates exploration of a potentially, greatly simplified
strategy to the important food toxin, aflatoxin. The envisioned asymmetric
route also may provide a simple protocol for the asymmetric synthesis of
physostigmines, one of whose members is a candidate for treatment of
myasthenia gravis, glaucoma, and Alzheimer's disease.
A third phase examines a new class of cycloaddition reactions to create odd
membered rings. Exploring a new class of acceptors in conjunction with a
novel class of reactive intermediates creates a conceptual framework to the
anthelmintic and antinematodal mold metabolites paraherquamide and
marcfortine. An unusual (6+3) cycloaddition may create strategies for the
structurally unusual farnesyl transferase inhibitor CP-263,114 and simpler
analogues. Ring expansion methods may convert these cores into the taxoid
skeleton with appropriate functionality at key points for analog
development.
DESCRIPTION: Exploring biological phenomena at a molecular level provides
the basis of understanding from which new therapeutic agents derive. The
ability to construct a defined molecular architecture requires highly
selective reactions and reagents to permit the development of effective
synthetic strategies. Cyclic compounds have biological activities across a
broad spectrum. Furthermore, constraining conformations of mobile molecules
by forming rings also frequently enhances biological potency. Thus, a
concerted effort to apply new chemical principles being developed in the
PI's laboratories to the formation of rings becomes an important objective.
In the first phase, a new concept to create macrocycles (rings larger than
seven members) may provide a unique opportunity to approach a variety of
significant targets. Some examples include the antiinflammatory nine
membered macrolides ascidiatrienolides, the antitumor eight membered
carbocycles, the shikoccins, and the azocines, FR-99048 and FR-66979, the
ten membered macrolactam neuropeptidase inhibitor CGS-25155, the fourteen
membered antiviral and antifungal fluviricinines, and the nineteen membered
serine protease inhibitors, the cyclotheonamides. In the second phase, a
new reactivity mode for shuffling protons in totally unconventional methods
offers novel approaches to cyclizations. Vitamin D analogues and
derivatives represent a most important direction for creation of clinically
important therapeutic agents. A new concept for their synthesis based upon
novel strategies for asymmetric induction will be pursued. A variation on
this methodology may extend the reaction to a facile asymmetric synthesis of
either cis or trans fused drimanes and related classes of terpenoids from a
common intermediate, a class of compounds that have remarkably broad
biological activities including antibacterial, antifungal, antimalarial,
antiinflammatory, cytotoxic, and insecticidal. A new class of reactions
provides a novel atom economical approach for formation of heterocycles.
This invention stimulates exploration of a potentially, greatly simplified
strategy to the important food toxin, aflatoxin. The envisioned asymmetric
route also may provide a simple protocol for the asymmetric synthesis of
physostigmines, one of whose members is a candidate for treatment of
myasthenia gravis, glaucoma, and Alzheimer's disease.
A third phase examines a new class of cycloaddition reactions to create odd
membered rings. Exploring a new class of acceptors in conjunction with a
novel class of reactive intermediates creates a conceptual framework to the
anthelmintic and antinematodal mold metabolites paraherquamide and
marcfortine. An unusual (6+3) cycloaddition may create strategies for the
structurally unusual farnesyl transferase inhibitor CP-263,114 and simpler
analogues. Ring expansion methods may convert these cores into the taxoid
skeleton with appropriate functionality at key points for analog
development.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(7)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BARRY M TROST其他文献
BARRY M TROST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BARRY M TROST', 18)}}的其他基金
NOVEL SYNTHETIC APPROACHES TO ANTITUMOR COMPOUNDS:
抗肿瘤化合物的新合成方法:
- 批准号:
7724151 - 财政年份:2008
- 资助金额:
$ 44.06万 - 项目类别:
MACROLIDES, STEROIDS, CYCLOPENTANOIDS, ETC SYNTHETIC DESIGNS
大环内酯类、类固醇类、环戊类化合物等合成设计
- 批准号:
7724152 - 财政年份:2008
- 资助金额:
$ 44.06万 - 项目类别:
MACROLIDES, STEROIDS, CYCLOPENTANOIDS, ETC SYNTHETIC DESIGNS
大环内酯类、类固醇类、环戊类化合物等合成设计
- 批准号:
7601802 - 财政年份:2007
- 资助金额:
$ 44.06万 - 项目类别:
NOVEL SYNTHETIC APPROACHES TO ANTITUMOR COMPOUNDS: ANTIVIRALS, HIV
抗肿瘤化合物的新合成方法:抗病毒药物、HIV
- 批准号:
7601801 - 财政年份:2007
- 资助金额:
$ 44.06万 - 项目类别:
MACROLIDES, STEROIDS, CYCLOPENTANOIDS, ETC SYNTHETIC DESIGNS
大环内酯类、类固醇类、环戊类化合物等合成设计
- 批准号:
7369021 - 财政年份:2006
- 资助金额:
$ 44.06万 - 项目类别:
NOVEL SYNTHETIC APPROACHES TO ANTITUMOR COMPOUNDS: ANTIVIRAL AGENTS, HIV
抗肿瘤化合物的新合成方法:抗病毒药物、HIV
- 批准号:
7369020 - 财政年份:2006
- 资助金额:
$ 44.06万 - 项目类别:
MACROLIDES, STEROIDS, CYCLOPENTANOIDS, ETC SYNTHETIC DESIGNS
大环内酯类、类固醇类、环戊类化合物等合成设计
- 批准号:
7180903 - 财政年份:2005
- 资助金额:
$ 44.06万 - 项目类别:
NOVEL SYNTHETIC APPROACHES TO ANTITUMOR COMPOUNDS: ANTIVIRAL AGENTS, HIV
抗肿瘤化合物的新合成方法:抗病毒药物、HIV
- 批准号:
7180902 - 财政年份:2005
- 资助金额:
$ 44.06万 - 项目类别:
NOVEL SYNTHETIC APPROACHES TO ANTITUMOR COMPOUNDS: ANTIVIRAL AGENTS, HIV
抗肿瘤化合物的新合成方法:抗病毒药物、HIV
- 批准号:
6976589 - 财政年份:2004
- 资助金额:
$ 44.06万 - 项目类别:
MACROLIDES, STEROIDS, CYCLOPENTANOIDS, ETC SYNTHETIC DESIGNS
大环内酯类、类固醇类、环戊类化合物等合成设计
- 批准号:
6976590 - 财政年份:2004
- 资助金额:
$ 44.06万 - 项目类别:
相似海外基金
Extending the utility and durability of antifungal agents via innovative treatment regimens that minimise drug resistance
通过创新治疗方案最大限度地减少耐药性,延长抗真菌药物的效用和持久性
- 批准号:
MR/Y002164/1 - 财政年份:2024
- 资助金额:
$ 44.06万 - 项目类别:
Research Grant
Engineering microbial cell factories for production of improved polyene antifungal agents
工程微生物细胞工厂用于生产改进的多烯抗真菌剂
- 批准号:
2898887 - 财政年份:2023
- 资助金额:
$ 44.06万 - 项目类别:
Studentship
Morphological profiling for the development of antifungal agents
用于开发抗真菌药物的形态分析
- 批准号:
22H02216 - 财政年份:2022
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
An efficient approach to find therapeutically effective antifungal agents
寻找治疗有效的抗真菌药物的有效方法
- 批准号:
22K05337 - 财政年份:2022
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating light-activated therapeutic compounds as antifungal agents.
研究光激活治疗化合物作为抗真菌剂。
- 批准号:
2753345 - 财政年份:2022
- 资助金额:
$ 44.06万 - 项目类别:
Studentship
Discovery of novel therapeutic agents for biliary tract and pancreatic cancer based on antifungal agents
基于抗真菌药物的胆道癌和胰腺癌新型治疗药物的发现
- 批准号:
20H03533 - 财政年份:2020
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of antifungal agents that target essential protein kinases in A. fumigatus.
开发针对烟曲霉必需蛋白激酶的抗真菌剂。
- 批准号:
2456629 - 财政年份:2020
- 资助金额:
$ 44.06万 - 项目类别:
Studentship
Elucidation of tip growth factor of fungi and construction of screeing system for antifungal agents
真菌尖端生长因子的阐明及抗真菌药物筛选体系的构建
- 批准号:
19K05738 - 财政年份:2019
- 资助金额:
$ 44.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Ambruticins: An inspiration to develop novel biocatalysts and antifungal agents
Ambruticins:开发新型生物催化剂和抗真菌剂的灵感
- 批准号:
2107517 - 财政年份:2018
- 资助金额:
$ 44.06万 - 项目类别:
Studentship